Inactive Sars-Cov-2 Vaccine
SARS-CoV-2 Acute Respiratory Disease
Xijing HospitalvaccineActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
31 Active assets in the SARS-CoV-2 Acute Respiratory Disease cohort.
View all 50 →
Same molecule, other indications
Inactive Sars-Cov-2 Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →